TY - JOUR T1 - Extending Delivery of Seasonal Malaria Chemoprevention to Children Aged 5–10 Years in Chad: A Mixed-Methods Study JF - Global Health: Science and Practice JO - GLOB HEALTH SCI PRACT DO - 10.9745/GHSP-D-21-00161 VL - 10 IS - 1 SP - e2100161 AU - Azoukalné Moukénet AU - Laura Donovan AU - Beakgoubé Honoré AU - Kevin Baker AU - Helen Smith AU - Sol Richardson AU - Charlotte Ward Y1 - 2022/02/28 UR - http://www.ghspjournal.org/content/10/1/e2100161.abstract N2 - Key FindingsExtending the age eligibility for seasonal malaria chemoprevention to children aged 5–10 years is generally regarded as acceptable by key informants in Massaguet district, Chad.Decision makers at the policy level consider it more urgent to achieve full coverage, demonstrate impact, and ensure the sustainability of SMC administration in children aged 3–59 months in the current program.Key ImplicationsLeakage in the current program, resulting in children aged older than 59 months receiving SMC, is commonly acknowledged at all levels of the health system. To address this, program managers should consider more stringent selection criteria for community distributors, as well as more frequent training and more extensive sensitization at the community level.Background:To prevent malaria among children aged 3–59 months in areas with high seasonal transmission, seasonal malaria chemoprevention (SMC) is recommended. In Chad, there is evidence of SMC administration to children aged older than 5 years (referred to as “leakage”). This study aimed to understand the reasons for leakage and explore the feasibility and acceptability of extending the delivery of SMC to children aged 5–10 years in Chad.Methods:We conducted a mixed-methods study in Massaguet health district with a cross-sectional survey to determine SMC coverage for children aged up to 10 years after SMC cycles 1 and 3 (n=90 and n=100 caregivers surveyed, respectively) and at the end of cycle 4 (n=101 caregivers surveyed). We conducted 14 key informant interviews at the national and district level and 8 focus group discussions with community distributors and caregivers.Results:In the compounds surveyed, there were no children aged 5–10 years in cycle 1. In cycles 3 (n=1 children) and 4 (n=16 children), there was 100% (95% confidence interval [CI]=2.5, 100.0) and 62.5% (95% CI=35.4, 84.8) coverage of SMC in children aged 5–10 years, respectively. Extension of SMC to older children was considered acceptable, but there were concerns about feasibility and ensuring the sustainability of the current program in children aged 3–59 months. Key informants acknowledged the need to secure additional funding to pilot SMC in older age groups and were uncertain about the impact of the current SMC program at scale.Conclusion:Key informants considered extending SMC to children aged 5–10 years acceptable but did not deem it a current priority. They expressed an urgent need to address leakage and reinforce both the sustainability and quality of the current SMC program. ER -